open access
Vol 72, No 6 (2021)
Editorial
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-12-30
Get Citation
Flozins — in the light of the latest recommendations
1
, 1, 1
, 1, 1
Affiliations- Department of Internal Medicine, Diabetology, and Cardiometabolic Disorders, Faculty of Medical Sciences Zabrze, Medical University of Silesia in Katowice, Zabrze, Poland
open access
Vol 72, No 6 (2021)
Editorial
Submitted: 2021-10-03
Accepted: 2021-10-05
Published online: 2021-12-30
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Flozins — in the light of the latest recommendations
Journal
Issue
Article type
Editorial
Pages
589-591
Published online
2021-12-30
Page views
6125
Article views/downloads
717
DOI
Pubmed
Bibliographic record
Endokrynol Pol 2021;72(6):589-591.
Authors
Marta Wróbel
Dominika Rokicka
Krzysztof Strojek
References (16)- Sieradzki J. Cukrzyca. Via Medica, Gdańsk 2019.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- Wiviott S, Raz I, Bonaca M, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. New Engl J Med. 2019; 380(4): 347–357.
- Neal B, Perkovic V, Mahaffey KW, et al. CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7): 644–657.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381(21): 1995–2008.
- Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24): 2295–2306.
- Packer M, Butler J, Filippatos G, et al. Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial. Eur J Heart Fail. 2019; 21(10): 1270–1278.
- Anker SD, Butler J, Filippatos G, et al. EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 [Epub ahead of print].
- Mason T, Coelho-Filho O, Verma S, et al. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC: Cardiovasc Imag. 2021; 14(6): 1164–1173.
- Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci (Lond). 2018; 132(12): 1329–1339.
- Heerspink HJL, Stefansson BV, Chertow GM, et al. DAPA-CKD Investigators. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant. 2020; 35(2): 274–282.
- Cosentino F, Grant PJ, Aboyans V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41(2): 255–323.
- Buse JB, Wexler DJ, Tsapas A, et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43(2): 487–493.
- Araszkiewicz A, Bandurska-Stankiewicz E, Borys S, et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clin Diabetol. 2021; 10(1).
- Seferović P, Coats A, Ponikowski P, et al. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure. Eur J Heart Fail. 2020; 22(2): 196–213.
- Karagiannis T, Tsapas A, Bekiari E. KDIGO made 12 recommendations for managing diabetes with CKD. Ann Int Med. 2021; 174(3): JC26.
